|Dr. Fred B. Parks Ph.D.||Interim Pres, CEO & Director||47.5k||N/A||1947|
|Ms. Jennifer J. Kosharek||Interim CFO, VP, Controller & Principal Accounting Officer||N/A||N/A||1982|
|Mr. Benjamin Tranchina||Chief Technology Officer||N/A||N/A||N/A|
|Ms. Melissa G. Beare||Exec. VP, Gen. Counsel & Corp. Sec.||N/A||N/A||1975|
|Ms. Bonnie Schmidt||Exec. Director of HR||N/A||N/A||N/A|
Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs. It is also developing Virtis, a sacral neuromodulation (SNM) system for the treatment of chronic urinary retention and overactive bladder; and technologies to support other indications, including SNM for the treatment of overactive bladder and deep brain stimulation to treat Parkinson's disease. The company serves hospitals, surgery centers, and medical facilities through a direct sales force and third-party distributors in the United States and Europe. Nuvectra Corporation was founded in 2008 and is headquartered in Plano, Texas.
Nuvectra Corporation’s ISS Governance QualityScore as of July 29, 2019 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 9.